New data show Striverdi® (olodaterol)* Respimat® improves exercise tolerance in patients with moderate to very severe COPD
29 October 2013 | By Boehringer Ingelheim
“Exercise is an essential component of COPD management..."
List view / Grid view
News
Howie Mandel challenges people to learn the fibs and facts about atrial fibrillation and its associated increased stroke risk
28 October 2013 | By Bristol-Myers Squibb
“Fibs or Facts” educational program launches today to help raise up to $25,000 for National Stroke Association...
Promising phase IIb data on Clazakizumab in patients with moderate-to-severe rheumatoid arthritis to be presented
28 October 2013 | By Bristol-Myers Squibb Company
Clazakizumab is a humanized anti-IL-6 monoclonal antibody directed against the IL-6 cytokine rather than the receptor...
Global Lung Cancer Coalition to identify patient challenges and improve support strategies in partnership with Boehringer Ingelheim
28 October 2013 | By Boehringer Ingelheim
'Lung Cancer: We're Listening' will gather much needed feedback from individuals touched by lung cancer...
New two-year results show SIMPONI® ARIA™ (GOLIMUMAB) for infusion inhibited radiographic progression in patients with active rheumatoid arthritis
28 October 2013 | By Johnson & Johnson
Nearly 70 percent of patients receiving SIMPONI ARIA at two years demonstrated ACR 20 response...
Ethicon receives 510(K) clearance for new HARMONIC ACE®+ 7 SHEARS with advanced hemostasis
28 October 2013 | By Johnson & Johnson
Breakthrough technology in ultrasonic energy designed to improve surgeon confidence in vessel sealing...
Promising phase IIb data on Clazakizumab in patients with moderate-to-severe Rheumatoid Arthritis to be presented
28 October 2013 | By Bristol-Myers Squibb Company
Clazakizumab is a humanized anti-IL-6 monoclonal antibody that is directed against the IL-6 cytokine...
New efficacy and safety data adds to evidence suppoith afatinib*(GIOTRIF®) in Asian and non-Asian lung cancer patients
27 October 2013 | By Boehringer Ingelheim
"The new sub-analysis confirms the consistent safety profile of afatinib in Asian patients..."
Roche and Chugai’s investigational RoActemra® (tocilizumab) subcutaneous formulation shows comparable long-term efficacy and tolerability to the intravenous formulation in rheumatoid arthritis
26 October 2013 | By Just:: Health Communications
“These data show that RoActemra can continue to deliver meaningful improvements for people living with rheumatoid arthritis..."
GSK to create a new Centre of Excellence for Sustainable Chemistry in Brazil
25 October 2013 | By GlaxoSmithKline
"GSK has a vibrant and growing business in Brazil and we are delighted to announce our support for the new sustainable chemistry centre..."
Abbott’s first-in-class MitraClip® device now available for U.S. patients
25 October 2013 | By Abbott
"With the MitraClip system, heart teams now have a catheter-based, less-invasive treatment option..."
FDA Advisory Committee recommends approval of Simeprevir for combination treatment of genotype 1 chronic hepatitis C in adult patients
24 October 2013 | By Johnson & Johnson
Antiviral Drugs Advisory Committee of the U.S. Food and Drug Administration voted unanimously to recommend approval of the investigational protease inhibitor simeprevir...
Merck provides update on investigational 9-valent HPV vaccine V503 to U.S. Advisory Committee on immunization practices
24 October 2013 | By Merck
The study evaluated the efficacy, immunogenicity and safety of V503 in females 16-26 years of age...
AstraZeneca announces proposal to close Brixham Environmental Laboratory
24 October 2013 | By AstraZeneca
The proposal to close the site has been made as the work undertaken at the laboratory is outside the organisation’s strategic focus...
Amgen promotes two senior executives: names Brian McNamee executive vice president and Stuart Tross senior vice president
24 October 2013 | By Amgen
McNamee will be responsible for leading a series of multi-year initiatives aimed at delivering growth and increasing productivity...
